STOCK TITAN

Nantahala discloses 9.03% Bioventus (BVS) stake in Schedule 13G/A

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Nantahala Capital Management, LLC, together with Wilmot B. Harkey and Daniel Mack, reports beneficial ownership of Bioventus Inc. Class A common stock on a Schedule 13G/A amendment. As of December 31, 2025, they may be deemed to beneficially own 6,047,403 shares, representing 9.03% of the outstanding Class A shares.

The reporting persons have shared power to vote and dispose of all 6,047,403 shares through funds and separately managed accounts controlled by Nantahala, and no sole voting or dispositive power. They state the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Bioventus.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Nantahala Capital Management, LLC
Signature:/s/ Taki Vasilakis
Name/Title:Taki Vasilakis / Chief Compliance Officer
Date:02/13/2026
Wilmot B. Harkey
Signature:/s/ Wilmot B. Harkey
Name/Title:Wilmot B. Harkey
Date:02/13/2026
Daniel Mack
Signature:/s/ Daniel Mack
Name/Title:Daniel Mack
Date:02/13/2026

FAQ

What ownership stake in Bioventus (BVS) does Nantahala report in this Schedule 13G/A?

The filing reports that Nantahala and its related reporting persons may be deemed to beneficially own 6,047,403 shares of Bioventus Class A common stock, representing 9.03% of the outstanding class as of December 31, 2025.

Who are the reporting persons on this Bioventus (BVS) Schedule 13G/A filing?

The reporting persons are Nantahala Capital Management, LLC, Wilmot B. Harkey, and Daniel Mack. Nantahala is a Massachusetts limited liability company, while Harkey and Mack are citizens of the United States and managing members of Nantahala.

How much voting and dispositive power do the reporting persons have over Bioventus (BVS) shares?

Each reporting person reports 0 shares of sole voting and dispositive power, and 6,047,403 shares of shared voting and shared dispositive power. These shares are held by funds and separately managed accounts under Nantahala’s control.

As of what date is the Bioventus (BVS) ownership information in this Schedule 13G/A effective?

The ownership information is stated as of December 31, 2025, which is the date of the event requiring the filing. Percentages and share counts in the filing are tied specifically to that date for Bioventus Class A common stock.

What is the stated purpose of holding Bioventus (BVS) shares by Nantahala and related persons?

The reporting persons certify the Bioventus securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer, except for activities related to a nomination under Rule 240.14a-11.

Under what capacity are Wilmot B. Harkey and Daniel Mack reporting Bioventus (BVS) ownership?

Harkey and Mack file as control persons with respect to shares beneficially owned by Nantahala, which is described as an investment adviser under Rule 240.13d-1(b)(1)(ii)(E). Each may be deemed a beneficial owner of the same 6,047,403 shares.
Bioventus Inc.

NASDAQ:BVS

BVS Rankings

BVS Latest News

BVS Latest SEC Filings

BVS Stock Data

542.51M
59.02M
11.77%
73.52%
2.75%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
DURHAM